tebentafusp-tebn · KIMMTRAK

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Unresectable or Metastatic Uveal Melanoma, Uveal Melanoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Melanoma · Phase 3 · investigational in the US

Also approved (4)
UK
  • Unresectable or metastatic uveal melanoma (HLA-A*02:01-positive adults)
Product first approved 2022immunocore.com
CA
  • Unresectable or metastatic uveal melanoma (HLA-A*02:01-positive adults)
Product first approved 2022immunocore.com
AU
  • Unresectable or metastatic uveal melanoma (HLA-A*02:01-positive adults)
Product first approved 2022immunocore.com
EU
  • Monotherapy for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
Product first approved 2022EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Melanoma
Uveal Melanoma
Phase 2 (9)
Melanoma
NCT05315258 · University of Oxford
2022-07-25 – 2027-06-30 · Melanoma (Skin), Melanoma, Uveal
What this study did
NCT02889861 · Immunocore Ltd
2017-01-11 – 2019-04-22 · Malignant Melanoma
What this study did
Uveal Melanoma
NCT06414590 · Thomas Jefferson University
2025-09-05 – 2032-03 · Locally Advanced Unresectable Uveal Melanoma
What this study did
NCT06627244 · University of Miami
2025-02-14 – 2031-02-17 · Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
What this study did
NCT07276386 · H. Lee Moffitt Cancer Center and Research Institute
2025-12-31 – 2030-12 · Metastatic Uveal Melanoma
What this study did
NCT06070012 · Diwakar Davar
2025-08-18 – 2030-09-30 · Uveal Melanoma
What this study did
NCT07057596 · Grupo Español Multidisciplinar de Melanoma
2025-07-18 – 2027-12 · Mestastatic Uveal Melanoma
What this study did
Other / comorbidity
NCT06942442 · Sarcoma Alliance for Research through Collaboration
2025-10-22 – 2030-10-01 · HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS)
What this study did
Phase 1/2 (4)
Melanoma
NCT02535078 · Immunocore Ltd
2015-11 – 2023-09-06 · Malignant Melanoma
What this study did
Uveal Melanoma
NCT06626516 · Thomas Jefferson University
2025-10-15 – 2032-08 · Metastatic Uveal Melanoma
What this study did
NCT02570308 · Immunocore Ltd
2016-02-29 – 2022-10-17 · Uveal Melanoma
What this study did
Other / comorbidity
NCT04262466 · Immunocore Ltd
2020-02-25 – 2027-12 · Select Advanced Solid Tumors
What this study did
Phase 1 (3)
Melanoma
NCT01211262 · Immunocore Ltd
2010-09-28 – 2017-02-16 · Malignant Melanoma
What this study did
NCT01209676 · University of Pennsylvania
2010-09 – 2013-03 · Melanoma, Advanced Disease, Unresectable
What this study did
Other / comorbidity
NCT05785754 · DynamiCure Biotechnology
2023-06-28 – 2026-12 · Advanced or Metastatic Solid Tumors
What this study did

Competitive landscape

This drug's own stage for Melanoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tebentafusp-Tebn (KIMMTRAK): this drugPhase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow KIMMTRAK (tebentafusp-tebn) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Advanced or Metastatic Solid TumorsRecruiting
Est. primary completion 2026-12 · NCT05785754 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2026-12-30 · NCT05315258 · CT.gov ↗
What to watch
2027 (2)
August 2027 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2027-08 · NCT06414590 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2027-12 · NCT07057596 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-02-17 · NCT06627244 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3MelanomaRecruiting
Est. primary completion 2028-03 · NCT05549297 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-09-30 · NCT06070012 · CT.gov ↗
What to watch
2030 (3)
October 2030 (2)
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-10 · NCT06626516 · CT.gov ↗
What to watch
Phase 2HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS)Recruiting
Est. primary completion 2030-10-01 · NCT06942442 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2030-12 · NCT07276386 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 3MelanomaRecruiting
Est. primary completion 2032-11 · NCT06246149 · CT.gov ↗
What to watch

See the full readout calendar ↗